Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sung Kwang Medical Foundation
ClinicalTrials.gov Identifier:
NCT01193660
First received: August 29, 2010
Last updated: March 1, 2012
Last verified: March 2012
Results First Received: October 11, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Cerebral Palsy
Interventions: Biological: Umbilical Cord Blood Infusion
Drug: Erythropoietin Injection
Other: Active Rehabilitation
Other: Placebo Umbilical Cord Blood
Other: Placebo Erythropoietin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment Period: May 31, 2010 through April 9, 2011 All participants were recruited at CHA Bundang Medical Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
We tried to recruit 106 subjects. Finally 105 patients were enrolled at the beginning of the overall study and none of the participants were washed out before assignment to groups.

Reporting Groups
  Description
Umbilical Cord Blood & Erythropoietin & Rehabilitation Allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg intravenously), Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times), and active rehabilitation
Erythropoietin & Rehabilitation Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times),and active rehabilitation
Only Rehabilitation Active rehabilitation

Participant Flow:   Overall Study
    Umbilical Cord Blood & Erythropoietin & Rehabilitation     Erythropoietin & Rehabilitation     Only Rehabilitation  
STARTED     35     36     34  
COMPLETED     31     33     32  
NOT COMPLETED     4     3     2  
Withdrawal by Subject                 2                 3                 1  
Death                 1                 0                 0  
Physician Decision                 1                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Umbilical Cord Blood & Erythropoietin & Rehabilitation Allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg intravenously), Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times), and active rehabilitation
Erythropoietin & Rehabilitation Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times),and active rehabilitation
Only Rehabilitation Active rehabilitation
Total Total of all reporting groups

Baseline Measures
    Umbilical Cord Blood & Erythropoietin & Rehabilitation     Erythropoietin & Rehabilitation     Only Rehabilitation     Total  
Number of Participants  
[units: participants]
  35     36     34     105  
Age  
[units: participants]
       
<=18 years     35     36     34     105  
Between 18 and 65 years     0     0     0     0  
>=65 years     0     0     0     0  
Age  
[units: months]
Mean ± Standard Deviation
  45.71  ± 18.91     50.05  ± 24.45     46.0  ± 19.58     47.30  ± 21.07  
Gender  
[units: participants]
       
Female     13     11     9     33  
Male     22     25     25     72  
Region of Enrollment  
[units: participants]
       
Korea, Republic of     35     36     34     105  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Changes in Motor Performance   [ Time Frame: Baseline -1 month - 3 months - 6 months ]

2.  Primary:   Changes in Standardized Gross Motor Function   [ Time Frame: Baseline - 1 month - 3 months - 6 months ]

3.  Secondary:   Changes in Cognitive Neurodevelopmental Outcome   [ Time Frame: Baseline -1 month - 3 months - 6 months ]

4.  Secondary:   Changes in Motor Neurodevelopmental Outcome   [ Time Frame: Baseline - 1 month - 3 months - 6 months ]

5.  Secondary:   Changes in Brain MRI   [ Time Frame: Baseline - 6 months ]

6.  Secondary:   Comparison of Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET: Increased and Decreased Areas of Brain Glucose Metabolism   [ Time Frame: Baseline - 2 weeks ]

7.  Secondary:   Changes in Functional Performance in Daily Activities   [ Time Frame: Baseline -1 month - 3 months - 6 months ]

8.  Secondary:   Changes in Functional Independence in Daily Activities   [ Time Frame: Baseline - 1 month - 3 months - 6 months ]

9.  Secondary:   Changes in Muscle Strength   [ Time Frame: Baseline - 1 month - 3 months - 6 months ]

10.  Secondary:   Changes in Hand Function   [ Time Frame: Baseline - 1 month - 3 months - 6 months ]

11.  Secondary:   Number of Participants With Serious Adverse Events as a Measure of Safety,Which Are Related to Umbilical Cord Blood, Erythropoietin, or Immunosuppressant   [ Time Frame: 6 months ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Baseline - 1 month - 3 months - 6 months
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   0%  

Reporting Groups
  Description
Umbilical Cord Blood & Erythropoietin & Rehabilitation Allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg intravenously), Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times), and active rehabilitation
Erythropoietin & Rehabilitation Erythropoietin injection (twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times),and active rehabilitation
Only Rehabilitation Active rehabilitation

Other Adverse Events
    Umbilical Cord Blood & Erythropoietin & Rehabilitation     Erythropoietin & Rehabilitation     Only Rehabilitation  
Total, other (not including serious) adverse events        
# participants affected / at risk     30/35     29/36     32/34  
Blood and lymphatic system disorders        
Anemia † 1      
# participants affected / at risk     1/35 (2.86%)     0/0 (0.00%)     0/18 (0.00%)  
# events     1     0     0  
Ear and labyrinth disorders        
Otitis media acute † 1      
# participants affected / at risk     1/35 (2.86%)     1/14 (7.14%)     0/18 (0.00%)  
# events     1     1     0  
Eye disorders        
Conjunctival irritations † 1      
# participants affected / at risk     0/35 (0.00%)     1/14 (7.14%)     1/18 (5.56%)  
# events     0     1     2  
Gastrointestinal disorders        
Constipation † 1      
# participants affected / at risk     5/35 (14.29%)     4/14 (28.57%)     5/18 (27.78%)  
# events     5     4     5  
Dyspepsia † 1      
# participants affected / at risk     5/35 (14.29%)     2/36 (5.56%)     2/18 (11.11%)  
# events     5     2     2  
Nausea, vomiting † 1      
# participants affected / at risk     6/35 (17.14%)     5/36 (13.89%)     2/18 (11.11%)  
# events     6     5     2  
Diarrhea † 1      
# participants affected / at risk     6/35 (17.14%)     2/36 (5.56%)     2/18 (11.11%)  
# events     6     2     2  
Colitis † 1      
# participants affected / at risk     0/35 (0.00%)     1/14 (7.14%)     2/18 (11.11%)  
# events     0     1     2  
Anorexia † 1      
# participants affected / at risk     5/35 (14.29%)     2/36 (5.56%)     1/18 (5.56%)  
# events     5     2     1  
Infections and infestations        
Herpangina † 1      
# participants affected / at risk     0/35 (0.00%)     2/14 (14.29%)     1/18 (5.56%)  
# events     0     2     1  
Fever † 1      
# participants affected / at risk     12/35 (34.29%)     4/36 (11.11%)     8/18 (44.44%)  
# events     12     4     8  
Nervous system disorders        
Seizure † 1      
# participants affected / at risk     1/35 (2.86%)     3/36 (8.33%)     3/18 (16.67%)  
# events     1     6     7  
Febrile convulsioin † 1      
# participants affected / at risk     2/35 (5.71%)     1/14 (7.14%)     0/18 (0.00%)  
# events     3     1     0  
Psychiatric disorders        
Irritability † 1      
# participants affected / at risk     4/35 (11.43%)     0/14 (0.00%)     0/18 (0.00%)  
# events     4     0     0  
Insomnia † 1      
# participants affected / at risk     0/35 (0.00%)     1/36 (2.78%)     1/18 (5.56%)  
# events     0     1     1  
Respiratory, thoracic and mediastinal disorders        
Bronchitis † 1      
# participants affected / at risk     4/35 (11.43%)     4/14 (28.57%)     3/18 (16.67%)  
# events     4     4     3  
Pneumonia † 1      
# participants affected / at risk     6/35 (17.14%)     0/14 (0.00%)     0/18 (0.00%)  
# events     6     0     0  
Upper respiratory tract infection † 1      
# participants affected / at risk     18/35 (51.43%)     19/36 (52.78%)     21/34 (61.76%)  
# events     20     23     24  
Hypoxia † 1 [3]      
# participants affected / at risk     3/35 (8.57%)     1/36 (2.78%)     1/18 (5.56%)  
# events     3     1     1  
Skin and subcutaneous tissue disorders        
Dermatitis † 1      
# participants affected / at risk     0/35 (0.00%)     2/36 (5.56%)     2/18 (11.11%)  
# events     0     2     2  
Urticaria † 1      
# participants affected / at risk     2/35 (5.71%)     1/14 (7.14%)     4/18 (22.22%)  
# events     2     1     4  
Hirsuitism † 1      
# participants affected / at risk     2/35 (5.71%)     0/0 (0.00%)     0/0 (0.00%)  
# events     2     0     0  
Alopecia † 1      
# participants affected / at risk     1/35 (2.86%)     0/0 (0.00%)     0/0 (0.00%)  
# events     1     0     0  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.1
[3] Temporary O2 desaturation(89-91%) at the end of UCB infusion in UCB group; O2 desaturation(91%) shortly during sedation for PET in EPO group; O2 desaturation(71-95%) intermittently during 47 min maybe from postictal respiratory depression in control



  More Information